null Option on Immunovant

IMVT Stock  USD 18.39  0.45  2.51%   
Immunovant's latest option contracts expiring on October 17th 2025 are carrying combined implied volatility of 0.81 with a put-to-call open interest ratio of 0.61 over 39 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on October 17th 2025. The total put volume is at 300, with calls trading at the volume of 302. This yields a 0.99 put-to-call volume ratio.

Open Interest Against October 17th 2025 Option Contracts

Immunovant option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Immunovant's lending market. For example, when Immunovant's puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Immunovant, he or she must hedge the risk by shorting Immunovant stock over its option's life.
The chart above shows Immunovant's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Immunovant's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Immunovant's option, there is no secondary market available for investors to trade.

In The Money vs. Out of Money Option Contracts on Immunovant

Analyzing Immunovant's in-the-money options over time can help investors to take a profitable long position in Immunovant regardless of its overall volatility. This is especially true when Immunovant's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Immunovant's options could be used as guardians of the underlying stock as they move almost dollar for dollar with Immunovant's stock while costing only a fraction of its price.

Immunovant In The Money Call Balance

When Immunovant's strike price is surpassing the current stock price, the option contract against Immunovant stock is said to be in the money. When it comes to buying Immunovant's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Immunovant are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

Immunovant Current Options Market Mood

Immunovant's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Immunovant Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Unfortunately, most Immunovant's options investors are not very successful. Immunovant's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current Immunovant contract

Base on the Rule 16, the options market is currently suggesting that Immunovant will have an average daily up or down price movement of about 0.0506% per day over the life of the 2025-10-17 option contract. With Immunovant trading at USD 18.39, that is roughly USD 0.00931. If you think that the market is fully incorporating Immunovant's daily price movement you should consider buying Immunovant options at the current volatility level of 0.81%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Purchasing Immunovant options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Immunovant calls. Remember, the seller must deliver Immunovant stock to the call owner when a call is exercised.

Immunovant Option Chain

When Immunovant's strike price is surpassing the current stock price, the option contract against Immunovant stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Immunovant's option chain is a display of a range of information that helps investors for ways to trade options on Immunovant. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Immunovant. It also shows strike prices and maturity days for a Immunovant against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
IMVT251017C00035000035.00.0 - 0.950.95Out
Call
IMVT251017C000300003130.00.0 - 0.950.35Out
Call
IMVT251017C00029000429.00.0 - 2.02.0Out
Call
IMVT251017C00028000028.00.0 - 1.951.95Out
Call
IMVT251017C000270001027.00.0 - 1.751.75Out
Call
IMVT251017C00026000126.00.0 - 1.21.2Out
Call
IMVT251017C0002500031225.00.0 - 2.20.33Out
Call
IMVT251017C00024000124.00.0 - 2.250.24Out
Call
IMVT251017C00023000023.00.15 - 2.550.15Out
Call
IMVT251017C00022000122.00.0 - 2.62.6Out
Call
IMVT251017C000210005421.00.85 - 1.81.1Out
Call
IMVT251017C00020000102520.01.15 - 2.551.85Out
Call
IMVT251017C00019000519.01.5 - 2.852.75Out
Call
IMVT251017C000180001918.01.95 - 3.62.55In
Call
IMVT251017C00017000417.02.4 - 4.32.4In
Call
IMVT251017C000160006616.02.5 - 5.03.8In
Call
IMVT251017C00015000109515.03.2 - 5.44.2In
Call
IMVT251017C00014000114.03.9 - 6.73.83In
 Put
IMVT251017P00035000035.015.6 - 17.815.6In
 Put
IMVT251017P00030000030.010.7 - 13.110.7In
 Put
IMVT251017P00029000029.010.2 - 12.110.2In
 Put
IMVT251017P00028000028.08.4 - 11.28.4In
 Put
IMVT251017P00027000027.07.8 - 10.27.8In
 Put
IMVT251017P00026000026.07.3 - 9.17.3In
 Put
IMVT251017P00025000025.05.9 - 8.45.9In
 Put
IMVT251017P00024000024.05.0 - 7.65.0In
 Put
IMVT251017P00023000023.04.2 - 6.84.2In
 Put
IMVT251017P00022000022.03.4 - 6.43.4In
 Put
IMVT251017P00020000320.02.65 - 4.02.65In
 Put
IMVT251017P00019000519.01.85 - 3.51.85In
 Put
IMVT251017P00018000318.01.45 - 2.951.85Out
 Put
IMVT251017P000170001417.00.9 - 2.60.9Out
 Put
IMVT251017P00016000916.00.0 - 2.33.4Out
 Put
IMVT251017P0001500029915.00.0 - 2.11.5Out
 Put
IMVT251017P00014000314.00.0 - 2.62.6Out
 Put
IMVT251017P00013000113.00.0 - 1.951.75Out
 Put
IMVT251017P00012000126312.00.0 - 1.951.15Out
 Put
IMVT251017P00010000510.00.0 - 2.02.0Out
 Put
IMVT251017P0000700077.00.0 - 0.950.95Out

Immunovant Total Stockholder Equity

Total Stockholder Equity

363.22 Million

At this time, Immunovant's Total Stockholder Equity is comparatively stable compared to the past year.

Immunovant Corporate Management

Jay StoutChief OfficerProfile
Mark LevineChief SecretaryProfile
Lauren MBAVice MarketingProfile
JD EsqChief SecretaryProfile
Eva MBAChief OfficerProfile
Julie KirschlingSenior ManagementProfile
Christine BlodgettSenior ResourcesProfile

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.